VivoSeq
Oncology

Ovarian Carcinoma

62

Pipeline Programs↗

4

Active Trials↗

34

Companies Involved↗

Ovarian Carcinoma is a moderately active landscape with 62 programs across 34 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Moderna, Meitheal. 6 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

6/100

Mech. Concentration

8/100

Completion Rate

49/100

Attrition Rate

43/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1Moderna logo

Moderna

1 program

Phase 1M

Meitheal

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1AstraZeneca logo

AstraZeneca

6 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical3

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Gemcitabine Hydrochloride

Gynecologic Oncology Group

Itraconazole

Sebela Pharmaceuticals Development LLC

Phase 18

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Gemcitabine

Johnson & Johnson

Mrna-4659

Moderna

Topotecan

Meitheal

Fondaparinux

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 238

Docetaxel

Avyxa

Paclitaxel

Teva

Regorafenib

Bayer

BMS-986205

Bristol-Myers Squibb

BMS-986229

Bristol-Myers Squibb

Phase 37

Veliparib

AbbVie

Dostarlimab

Glaxo Dba Glaxosmithkline

Atezolizumab

Roche

Bevacizumab

Bio-Thera Solutions

Caelyx

Merck & Co.

Approved6

Methotrexate

Alnylam Pharmaceuticals

Cyclophosphamide

Baxter Healthcare Corporation

Lenvatinib

Eisai

Doxorubicin

Pfizer

Letrozole

Novartis

Analysis

Modality Breakdown

83%

Small molecule

49 of 59 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody712%Protein / enzyme12%RNA therapy12%Cell therapy12%

Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 97% of 70 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed17 · 40%
Terminated11 · 26%
Withdrawn7 · 17%
Unknown status3 · 7%
Not yet recruiting3 · 7%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

42 trials

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02487693·50 enrolled
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Not yet recruiting·JJin LI·Phase 2·NCT06081595·54 enrolled
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
Not yet recruiting·XXiaohua Wu MD·Phase 2·NCT05479487·132 enrolled
A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1/2 Deleterious Mutations or HRD-Positive Advanced/Metastatic Ovarian Cancer
Not yet recruiting·DDanatlas Pharmaceuticals Co., Ltd·Phase 2·NCT07652073·30 enrolled
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients
Completed·RRadboud University Medical Center·Phase 1·NCT03539406·11 enrolled
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00059787·56 enrolled
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT02584465·68 enrolled
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
Completed·AAGO Study Group·Phase 2·NCT00189358
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Completed·SSOTIO a.s.·Phase 2·NCT02107950·71 enrolled
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Completed·SSOTIO a.s.·Phase 2·NCT02107937·136 enrolled
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT03470805·9 enrolled
A Trial Evaluating TG4050 in Ovarian Carcinoma.
Completed·TTransgene·Phase 1·NCT03839524·64 enrolled
Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT00216645·74 enrolled
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Completed·IInstitut Bergonié·Phase 1·NCT03085225·40 enrolled
Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients
Completed·GGynecologic Oncology Associates·Phase 2·NCT00127920·20 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)